首页> 外文期刊>Gastrointestinal Endoscopy >Diagnostic utility of EUS-guided FNA in patients with gastric submucosal tumors.
【24h】

Diagnostic utility of EUS-guided FNA in patients with gastric submucosal tumors.

机译:EUS引导的FNA在胃黏膜下肿瘤患者中的诊断效用。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Submucosal tumors (SMTs) comprise both benign and malignant lesions, and most of the gastric lesions tend to be malignant. The addition of EUS-guided FNA (EUS-FNA) has the potential to improve this distinction, but published series are limited. OBJECTIVE: To evaluate the yield of EUS-FNA in gastric SMTs with referral to a criterion standard final diagnosis. DESIGN: Retrospective study. SETTING: Tertiary-care referral center. PATIENTS: This study involved 141 consecutive patients with gastric SMTs, who underwent EUS-FNA from January 2000 to December 2008. Immunohistochemical staining with c-kit, CD34, actin, and S-100 antibodies was done if a spindle cell tumor was found. Based on FNA sample adequacy, and whether a specific diagnosis could be established, EUS-FNA results were categorized as diagnostic, suggestive, or nondiagnostic. The criterion standards for final diagnosis were the surgical histopathological results or the follow-up course for malignant, inoperable cases. INTERVENTION: EUS-FNA. MAIN OUTCOME MEASUREMENTS: Diagnostic yield of EUS-FNA and factors related to sampling adequacy for cytological and immunohistochemical evaluation. RESULTS: A total of 141 patients (52% female, mean age 56.7 years) underwent EUS-FNA (range 1-5 passes). The overall results of EUS-FNA were diagnostic, suggestive, and nondiagnostic in 43.3%, 39%, and 17.7% of cases, respectively. Adequate specimens were obtained in 83% of cases, and 69 cases (48.9%) had a definitive final diagnosis. The most common gastric SMT was GI stromal tumor (59.5%). EUS-FNA results were 95.6% accurate (95% confidence interval [CI], 87.5%-99%) for the final diagnosis and 94.2% (95% CI, 85.6%-98.1%) accurate for differentiating potentially malignant lesions. A heterogeneous echo pattern was the only independent predictor for sampling adequacy (adjusted odds ratio 6.15; P = .002). There were no procedure-related complications. LIMITATIONS: Possibility of selection bias. CONCLUSION: EUS-FNA is an accurate method for diagnosis of gastric SMTs and for differentiating malignant lesions.
机译:背景:粘膜下肿瘤(SMT)既包括良性病变也包括恶性病变,大多数胃部病变倾向于是恶性的。 EUS指导的FNA(EUS-FNA)的添加有可能改善这种区别,但已发表的系列文章有限。目的:评估胃SMT中EUS-FNA的产量,并参考标准的最终诊断标准。设计:回顾性研究。单位:三级转诊中心。患者:这项研究包括从2000年1月至2008年12月接受EUS-FNA的141例连续胃SMT患者。如果发现纺锤状细胞肿瘤,则用c-kit,CD34,肌动蛋白和S-100抗体进行免疫组织化学染色。根据FNA样本的充分性以及是否可以建立特定的诊断,EUS-FNA的结果分为诊断性,提示性或非诊断性。最终诊断的标准标准是手术组织病理学结果或恶性,无法手术病例的随访过程。干预:EUS-FNA。主要观察指标:EUS-FNA的诊断率以及与细胞学和免疫组化评估的采样充分性相关的因素。结果:共有141例患者(女性52%,平均年龄56.7岁)接受了EUS-FNA(1-5次通过)。 EUS-FNA的总体结果分别为诊断性,提示性和非诊断性,分别占43.3%,39%和17.7%。在83%的病例中获得了足够的标本,有69例(48.9%)的病例得到了明确的最终诊断。胃SMT最常见的是胃肠道间质瘤(59.5%)。最终诊断的EUS-FNA结果准确度为95.6%(95%置信区间[CI],87.5%-99%),而鉴别潜在恶性病变的准确度为94.2%(95%CI,85.6%-98.1%)。异构回波模式是唯一的样本充足性独立预测因子(调整后的优势比为6.15; P = 0.002)。没有与手术相关的并发症。局限性:选择偏见的可能性。结论:EUS-FNA是诊断胃SMT和鉴别恶性病变的准确方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号